Essex Bio-Technology (HKSE:01061) Change In Payables And Accrued Expense : HK$0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Change In Payables And Accrued Expense?

Essex Bio-Technology's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was HK$0 Mil. It means Essex Bio-Technology's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Dec. 2024 .

Essex Bio-Technology's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was HK$0 Mil. It means Essex Bio-Technology's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Essex Bio-Technology Change In Payables And Accrued Expense Historical Data

The historical data trend for Essex Bio-Technology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology Change In Payables And Accrued Expense Chart

Essex Bio-Technology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Essex Bio-Technology Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Essex Bio-Technology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

Essex Bio-Technology Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Essex Bio-Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Change In Payables And Accrued Expense

Traded in Other Exchanges

N/A

Address

No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN

Website

http://www.essexbio.com

Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.

Executives

Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin	2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines